

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 221 315 A1**

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(43) Date of publication:
10.07.2002 Bulletin 2002/28

(21) Application number: **00963018.7**

(22) Date of filing: **29.09.2000**

(51) Int Cl.7: **A61K 31/198, A61K 9/70,
A61K 45/00, A61K 47/34,
A61K 47/14, A61P 27/12,
A61P 29/00, A61P 31/12,
A61P 37/06, A61P 43/00,
A61K 31/573**

(86) International application number:
PCT/JP00/06815

(87) International publication number:
WO 01/26648 (19.04.2001 Gazette 2001/16)

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(30) Priority: **13.10.1999 JP 29100299**

(71) Applicants:
• **Senju Pharmaceutical Co., Ltd.**
Osaka-shi, Osaka 541-0046 (JP)
• **Tojo, Kakuji**
Iizuka-shi, Fukuoka 820-0066 (JP)

(72) Inventors:
• **TOJO, Kakuji**
Iizuka-shi, Fukuoka 820-0066 (JP)
• **ISOWAKI, Akiharu**
Akashi-shi, Hyogo 673-0003 (JP)

(74) Representative:
von Kreisler, Alek, Dipl.-Chem. et al
Patentanwälte,
von Kreisler-Selting-Werner,
Bahnhofsvorplatz 1 (Deichmannhaus)
50667 Köln (DE)

(54) **OPHTHALMIC ADHESIVE PREPARATIONS FOR PERCUTANEOUS ABSORPTION**

(57) Ophthalmic transdermal patches are disclosed for treating diseases of the posterior segment of the eye comprising a drug-containing layer uniformly containing in a base matrix a percutaneous absorption enhancer, which is polyoxyethylene oleyl ether and/or isopropyl

myristate, and a drug to be delivered to the posterior segment of the eye including the lens, the vitreous body, the uvea and the retina.

BEST AVAILABLE COPY

EP 1 221 315 A1

Description

TECHNICAL FIELD

5 [0001] The present invention relates to ophthalmic transdermal patches for treating diseases of the posterior segment of the eye including the lens, the vitreous body, the choroid, and the retina. More specifically, the present invention relates to ophthalmic transdermal patches comprising predetermined one or more percutaneous absorption enhancers for improving transfer of a drug to ophthalmic tissues.

10 BACKGROUND ART

[0002] After administration of a drug in the form of eye drops or by subconjunctival injection, the concentration of the drug generally would reach, relatively with ease, therapeutically effective levels in the anterior segment of the eye including the cornea and the anterior aqueous humor. However, in tissues in the posterior segment of the eye, including
15 the lens, the vitreous humor, the choroid and the retina, which are located in deeper sites of the eye, the concentration of a drug generally would hardly, or almost never, reach therapeutically effective levels after its topical application either in the form of eye drops or by subconjunctival injection. Therefore, for diseases of the posterior segment of the eye, there have been tried different ways for administration of drugs, such as oral administration, intravenous drip, intrav-
20 itreous injection or intravitreal implant, in order to deliver the drug to tissues of the posterior segment of the eye. For example, in clinical studies of aldose reductase inhibitors for treating diabetic retinopathy and of immunosuppressant cyclosporine for treating uveitis accompanying Behçet's disease, oral route has been employed to administer those drugs. Ganciclovir, for example, which has been clinically applied as a therapeutic for cytomegalovirus infection of the uvea and the retina, has been administered by intravenous drip or in the form of an intravitreal implant. Furthermore, inhibitors of fibrosis such as triamcinolone acetonide, 5-fluorouracil and mitomycin C have been studied as therapeutics
25 for proliferative vitreoretinopathy, by the method of direct injection into the vitreous body.

[0003] However, for oral administration, those drugs generally must be taken several times a day, which would cause a concern about the patients' poor compliance. As to intravenous drip or intravitreal injection, on the other hand, indispensable frequent visit to the doctors would be a burden on the patients. Furthermore, with intravenous drip, there is a risk of causing side effects such as renal or hepatic disorders. Direct intravitreal injection could cause intravitreal
30 hemorrhage or could damage the retina. Intravitreal implants need a surgical operation, which would impose a burden on the patients and present risks entailed in a surgery.

[0004] As a system for administering a drug without imposing such a burden on patients, transdermal pharmaceutical preparations of estradiol and nicotine have been on the market. However, as for pharmaceutical preparations aimed to treat diseases localized in the eye by administering a drug through the skin, there is found only a report of a pilo-
35 carpine-containing transdermal preparation, which showed an intraocular pressure lowering effect comparable to that of pilocarpine eye drops (Japanese Laid-open Patent Application H8-509716). As a drug that has been used in the form of eye drops for inducing miosis to treat a specific type of glaucoma, pilocarpine is not required to act on the posterior segment of the eye. No attempt has been known before to deliver a drug to the posterior segment of the eye by making use of percutaneous absorption of the drug.

40 [0005] On this background, the objective of the present invention is to provide pharmaceutical preparations for delivering a drug to the posterior segment of the eye, that can eliminate the burden on the patients of frequent visit to the doctors or of a surgical operation, and that will make it easier to achieve improved patients' compliance.

DISCLOSURE OF INVENTION


45 [0006] Using drugs that, in light of their pharmacological effect, are desired to act on the very affected site of the posterior segment of the eye, the present inventors studied the transferability of the drugs to the eye by applying on the skin a base matrix containing them together with different compounds. As a result, the inventors found that the drugs can be delivered to the eye through the skin in other part of the body by enhancing percutaneous absorption
50 of the drugs by utilizing certain proper compounds, and that polyoxyethylene oleyl ether and isopropyl myristate are particularly preferred percutaneous absorption enhancers for this purpose.

[0007] Thus, the present invention provides an ophthalmic transdermal patch for treating diseases of the posterior segment of the eye comprising a drug-containing layer uniformly containing in a base matrix a percutaneous absorption enhancer and a drug to be delivered to at least a part of the posterior segment of the eye including the lens, the vitreous
55 body, the choroid and the retina.

[0008] The present invention further provides a method for treating a disease of at least a part of the posterior segment of the eye including the lens, the vitreous body, the choroid and the retina, in an animal, particularly a mammalian animal, and inter alia a human, wherein the method comprises applying to the animal an transdermal patch comprising

a drug-containing layer uniformly containing in a base matrix an effective amount of a drug to be delivered to the part and a percutaneous absorption enhancer.

[0009] Examples of the drugs used in the present invention include, but are not limited to, anti-cataract agents, anti-inflammatory agents, anti-viral agents, immunosuppressants, calcium channel antagonists, glutamate receptor antagonists and cysteine protease inhibitors, which in general will hardly, or almost never, reach the posterior segment of the eye by topical instillation or subconjunctival injection. Specific examples include a variety of steroidal drugs represented by anti-inflammatory steroids, and the compound of the formula (1)



and a pharmaceutically acceptable salt thereof, wherein R¹ denotes C1-C4 alkyl, or C6-C10 aryl which may be substituted, R² and R³ are the same or different from each other and denote hydrogen or C1-C4 alkyl, or are combined to form a C3-C7 ring, and R⁴ denotes aryl, cycloalkyl, or a lower alkyl which may be substituted with an aromatic heterocyclic ring.

BRIEF DESCRIPTION OF DRAWINGS

[0010]

Figure 1 is a schematic side view illustrating application of a piece of skin and a pharmaceutical preparation to one of the cells of a side-by-side type permeation experiment device.

Figure 2 is a graph showing in vitro prednisolone permeation through the skin with pharmaceutical preparations P2-P5.

Figure 3 is a graph showing in vitro prednisolone permeation through the skin with pharmaceutical preparations P6-P8.

Figure 4 is a graph showing in vitro prednisolone permeation through the skin with pharmaceutical preparations P9-P10.


Figure 5 is a graph showing in vitro SJA6017 permeation through the skin with pharmaceutical preparations S2-S4.

Figure 6 is a graph showing the profile of plasma concentration of the drugs after applying pharmaceutical preparations containing prednisolone or SJA6017.

Figure 7 is a schematic illustration of the shape of a SJA6017-containing patch and a rat to which the patch is applied.

BEST MODE FOR CARRYING OUT THE INVENTION

[0011] The compound of the formula (1) is described with a number of specific examples of its synthesis and test examples regarding its calpain inhibiting activity and preventive effect on lens opacification in Japanese Laid-open Patent Application No. H10-147564, the entirety of which is incorporated in this application by reference. The compound may be prepared, for example, according to the following reaction scheme, wherein the abbreviations are as defined hereinbefore.



Examples of the sulfonyl chloride represented by the general formula (II) (hereinafter also referred to as "compound (II)") include naphthalenesulfonyl chloride, toluenesulfonyl chloride, fluorobenzenesulfonyl chloride, chlorobenzenesulfonyl chloride, methanesulfonyl chloride, bromobenzenesulfonyl chloride, and benzenesulfonyl chloride.

40 [0012] Examples of the compound represented by the general formula (III) (hereinafter also referred to as "compound (III)") include glycine, alanine, valine, D-valine, norvaline, leucine, isoleucine, norleucine, tert-leucine, 1-aminocyclopropanecarboxylic acid, 1-aminocyclobutanecarboxylic acid, 1-aminocyclopentanecarboxylic acid, and 1-aminocyclohexanecarboxylic acid. The reaction between the compound (II) and the compound (III) may be carried out by well known methods, e.g., Shotten-Bauman reaction and the like.

45 [0013] The condensation of the compound represented by the general formula (IV) and N-hydroxysuccinimide is carried out in a conventionally employed solvent (e.g. tetrahydrofuran, dichloromethane, chloroform, and ethyl acetate) using a condensation agent. Examples of condensation agents suitable for use include N, N-dicyclohexylcarbodiimide and 1-ethyl-3-(3-dimethylamioethyl)carbodiimide hydrochloride. Examples of the aminoalcohol represented by the general formula (VI) (hereinafter also referred to as "compound (VI)") include valinol, leucinol, D-leucinol, phenylalaninol, tryptophanol, (S)-2-amino-3-cyclohexyl-1-propanol.

50 [0014] The reaction between the compound represented by the general formula (V) and the compound (VI) is carried out in a solvent such as tetrahydrofuran, dichloromethane, chloroform, ethyl acetate or the like, in the presence of a base (such as triethylamine, pyridine or the like). The compound (I) then may be prepared by oxidizing the compound represented by the general formula (VII) by an oxidizing agent (such as sulfur trioxide-pyridine complex, oxalyl chloride, pyridine chromate or the like). This reaction may be carried out at any desired temperature.

55 [0015] Within the scope of the compound thus obtained, examples of synthesis are described in the aforementioned patent document for the following species.

- (1) N-(2-naphthalenesulfonyl)-L-valyl-L-leucinal,
- (2) N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal,
- (3) N-(4-chlorophenylsulfonyl)-L-valyl-L-leucinal,
- (4) N-(4-methylphenylsulfonyl)-L-valyl-L-leucinal,
- 5 (5) N-(2-naphthalenesulfonyl)-L-tert-leucyl-L-leucinal,
- (6) N-(4-fluorophenylsulfonyl)-D-valyl-L-leucinal,
- (7) N-(4-fluorophenylsulfonyl)-L-norleucyl-L-leucinal,
- (8) N-(4-fluorophenylsulfonyl)-L-norvalyl-L-leucinal,
- (9) 1-(2-naphthalenesulfonylamino)cyclopentanecarbonyl-L-leucinal,
- 10 (10) N-(2-naphthalenesulfonyl)-L-tert-leucyl-L-phenylalaninal,
- (11) N-(4-fluorophenylsulfonyl)-L-valyl-L-phenylalaninal,
- (12) N-(2-naphthalenesulfonyl)-L-valyl-L-phenylalaninal,
- (13) N-(4-chlorophenylsulfonyl)-L-valyl-L-phenylalaninal,
- (14) N-(4-methylphenylsulfonyl)-L-valyl-L-phenylalaninal,
- 15 (15) 1-(2-naphthalenesulfonylamino)cyclohexanecarbonyl-L-phenylalaninal,
- (16) 1-(2-naphthalenesulfonylamino)cyclopentanecarbonyl-L-phenylalaninal,
- (17) N-(4-chlorophenylsulfonyl)-L-valyl-L-tryptophanal,
- (18) N-(4-fluorophenylsulfonyl)-L-valyl-L-tryptophanal,
- (19) 1-(2-naphthalenesulfonylamino)cyclohexanecarbonyl-L-tryptophanal,
- 20 (20) N-(2-naphthalenesulfonyl)-L-tert-leucyl-L-tryptophanal,
- (21) N-(4-fluorophenylsulfonyl)-L-valyl-L-cyclohexylalaninal,
- (22) N-(2-naphthalenesulfonyl)-L-valyl-L-cyclohexylalaninal,
- (23) N-(4-chlorophenylsulfonyl)-L-valyl-L-cyclohexylalaninal,
- (24) N-(4-fluorophenylsulfonyl)-D-valyl-D-leucinal,
- 25 (25) N-(4-fluorophenylsulfonyl)-L-valyl-D-leucinal,
- (26) N-(4-fluorophenylsulfonyl)-L-valyl-L-alaninal, and
- (27) N-methylsulfonyl-L-valyl-L-leucinal

[0016] In the same patent document, it is also reported that the compound possesses a cysteine protease inhibitor activity and therefore is useful as a drug for prevention or treatment of ischemic diseases, inflammation, cataract, retinopathy and the like. In the scope of the compound, examples particularly suitable to the purpose of the present invention include N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal or a pharmaceutically acceptable salt thereof.

[0017] In the present invention, especially suitable percutaneous absorption enhancers are, as mentioned, polyoxyethylene oleyl ether and isopropyl myristate, which may be used alone or in combination. When used alone, their content in the drug-containing layer is preferably in the range of 5-30 W/W% for polyoxyethylene oleyl ether, and 5-30 W/W% also for isopropyl myristate. Though they may be used in combination as desired, it is particularly preferable that the ratio of the content by weight concentration (W/W%) of polyoxyethylene oleyl ether to isopropyl myristate falls in the range of 1:0.1-1:5 in the drug-containing layer.

[0018] The content of polyoxyethylene oleyl ether in the drug-containing layer is more preferably 10-30 W/W%, still more preferably 10-20 W/W%, and most preferably 10-15 W/W%.

[0019] The content of isopropyl myristate in the drug-containing layer is more preferably 10-30 W/W%, still more preferably 10-20 W/W%, and most preferably 10-15 W/W%. Combined use of polyoxyethylene oleyl ether and isopropyl myristate further enhances percutaneous absorption of drugs.

[0020] In addition to polyoxyethylene oleyl ether and/or isopropyl myristate, the ophthalmic transdermal patches of the present invention may contain other supplementary percutaneous absorption enhancers known in the art. Examples of such percutaneous absorption enhancers include salts of N-acylsarcosine such as salts (sodium, potassium, magnesium, calcium, aluminum salts or the like) of N-lauroylsarcosine, cocoyl sarcosine, N-stearoylsarcosine, oleoylsarcosine, palmitoylsarcosine and the like, salts of higher fatty acids such as salts (sodium, potassium, magnesium, calcium, aluminum salts or the like) of capric acid, myristic acid, palmitic acid, lauric acid, stearic acid, palmitoleic acid, oleic acid, vaccenic acid, linolic acid, linolenic acid and the like, esters of higher fatty acids such as esters of capric acid, lauric acid, palmitic acid, stearic acid and the like with alcohols (methanol, ethanol, propanol, isopropanol, butanol, hexanol, pentanol, heptanol and the like), hydroxydicarboxylic acids and dicarboxylic acids such as lactic acid, malic acid, tartaric acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, fumaric acid, maleic acid and the like, monoterpenes such as 1-menthol, d-limonene and the like, surfactants such as sodium lauryl sulfate, sodium dodecylbenzenesulfonate, sodium alkylidiphenylether-disulfonate, dioctyl sulfosuccinates, ammonium polyoxyalkyl phenyl ether sulfate and the like, alcohols such as ethanol, glycerol, diethylene glycol, propylene glycol, polyethylene glycol, higher alcohols and the like, dimethyl sulfoxide, alkyl or methyl derivatives of salicylic acid, urea, dimethylacetamide, dimethylformamide and the like, pyrrolidone derivatives such as

polyvinylpyrrolidone, dodecylpyrrolidone, methylpyrrolidone and the like, and liquid vaseline, liquid paraffin, allantoin, squalene, Carbopol, vaseline, gelatin, amino acids, dodecylazacycloheptane-2-one and the like.

[0021] The base matrix that is particularly preferable comprises acrylic adhesives, silicone-based elastomers or styrene-isoprene-styrene copolymers, from which one can choose as desired. The matrix may be supported on a surface of one of supporting materials conventionally used in pharmaceutical preparations applied to the skin such as tapes, patches, poultices and the like, or any other support made of a material that will not affect the use of the present invention.

[0022] As for acrylic adhesive matrix, for example, acrylic copolymer resin PE-300 (solid content 40 %), a product of NIPPON CARBIDE INDUSTRIES CO., INC., may be used as an adhesive, and CK-401 (solid content 10-15 %), a product of NIPPON CARBIDE INDUSTRIES CO., INC., as a coagulation enhancer.

[0023] As for silicone-based matrix, for example, SLASTIC® MDX40-4210, a product of DOW CORNING ASIA, may be used as a silicone elastomer, and 360 MEDICAL FLUID, 20 cs, a product of DOW CORNING ASIA, as silicone oil. When providing an adhesive layer on the surface of the drug-containing layer comprising silicone-based matrix, for example, a silicone-based adhesive may be selected as desired from commercially available ones such as BIO-PSAQ7-4501 or BIO-PSAX7-4201, products of DOW CORNING ASIA, polymethylphenylsiloxane copolymer of LINTEC CORPORATION, or acrylic acid-dimethylsiloxane copolymer such as BPK-1, BPK-2 of WAKO PURE CHEMICAL INDUSTRIES, LTD. and the like.

[0024] As a styrene-isoprene-styrene copolymer, CARIFLEX TR-1107 and CARIFLEX TR-1111 of SHELL CHEMICAL, and JSR5000 of NIHON SYNTHETIC RUBBER are suitably used.

[0025] The concentration of the drug contained in the base matrix may be 1-20 W/W%, preferably 2-15 W/W%, and adjusted as desired in accordance with the disease to be treated and its severity.

[0026] In the polyoxyethylene oleyl ether used in the present invention, the average number of ethylene oxide added per oleyl moiety is preferably 4.4-5.5, and especially preferably about 5. It can be obtained by reacting oleyl alcohol with ethylene oxide having a hydroxyl group value of 4.5-5.5 as determined by the method described in the section of "Hydroxyl Group Value" in Testing Method for Fats and Oils in the Japanese Pharmacopoeia, 13th ed. For example, NOFABLE EAO-9905 of NOF CORPORATION may be favorably used.

[0027] The diseases of the posterior segment of the eye which are treated by the present invention are, for example, diseases of the lens, the vitreous body, the uvea including the choroid, or the retina, such as diabetic cataract, acute retinal necrosis syndrome, cytomegalovirus retinitis, intrinsic uveitis caused by autoimmune mechanism or abnormal immune response, proliferative vitreoretinopathy, diabetic retinopathy, retinal vessel occlusion, retinal periphlebitis, ischemic oculopathy, disorders of retinal vessels such as retinal aneurysm, retinopathy caused by ocular hypertension, nephropathy or hemopathy, retinal pigment epitheliopathy, retinal dystrophy, macular dystrophy, retinochoroidal atrophy, chorioretinopathy, macular dystrophy, macular edema, retinal pigment epithelium detachment, retinal detachment, degenerative retinoschisis, tumors such as retinoblastoma, retinal pigment epithelial tumor and tumor in optic disc capillary, optic neuropathy such as ischemic optic neuropathy, disc swelling such as choked disc and papilledema, open angle glaucoma, low tension glaucoma, angle closure glaucoma and the like.

[0028] Examples of drugs used in the present invention include aldose reductase inhibitors, corticosteroids (e.g. prednisolone, triamcinolone acetonide, dexamethasone), anti-viral agents (e.g., acyclovir, ganciclovir), immunosuppressants (e.g., cyclosporine), calcium ion channel antagonists (e.g., flunarizine, nifedipine, nicardipine), glutamate receptor antagonists (e.g., memantine, dizocilpine, dextrometorphan), and cysteine protease inhibitors [e.g., a compound represented by the formula (1), in particular N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal].

[0029] In use, the ophthalmic transdermal patches of the present invention may be applied at any location of the body surface as desired. It may be applied on a site relatively close to the eye, e.g., on the temple or around the eye, in particular on the skin of the eyelids or next to the lateral angle of the eye.

[Test Example]

[0030] The effect of transdermal patches of the present invention will be described below referring to test examples.

(1) Transdermal patches used

[0031] According to the formulas shown in Tables 1 and 2, transdermal patches were prepared containing prednisolone or N-(4-fluorophenyl-sulfonyl)-L-valyl-L-leucinal (hereinafter also referred to as "SJA6017"), respectively. In the tables, "%" means "W/W%" for the weight of the solid components. The concentration of the drugs (W/W%) were calculated as "drug/(drug + percutaneous absorption enhancers + acrylic adhesive + coagulation enhancer) x 100". EAO9905 indicates polyoxyethylene oleyl ether (NOFABLE EAO-9905: NOF CORPORATION) and IPM indicates isopropyl myristate.

[0032] Acrylic copolymer base matrix was prepared from an acrylic adhesive consisting of 40 % acrylate copolymer

solution in acetic acid and toluene (PE300: NIPPON CARBIDE INDUSTRIES CO., INC.) and a coagulation enhancer consisting of an approx. 7-10 % cross-linking agent solution in ethyl acetate and toluene (CK401: NIPPON CARBIDE INDUSTRIES CO., INC.), by mixing and reacting the acrylate copolymer and the cross-linking agent at a ratio of 100:1 by weight.

5

(a) Formula of transdermal patches containing prednisolone

[0033]

10

Table 1

Preparation No.	Prednisolone (%)	EAO9905 (%)	IPM (%)	Acrylate copolymer (+ cross-linking agent) (%)
P1 (Control)	3	0	0	97
P2	3	10	10	77
P3	3	10	20	67
P4	3	20	10	67
P5	3	20	20	57
P6	3	5	0	92
P7	3	10	0	87
P8	3	20	0	77
P9	3	0	10	87
P10	3	0	20	77

15

20

25

(b) Formula of transdermal patches containing N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal

30 [0034]

Table 2

Preparation No.	SJA6017 (%)	EAO9905 (%)	IPM (%)	Acrylate copolymer (+ cross-linking agent) (%)
S1 (Control)	5	0	0	95
S2	5	20	0	75
S3	5	20	10	65
S4	5	20	20	55

35

40

(2) Device for percutaneous permeation experiment

[0035] In percutaneous permeation experiment, a side-by-side type cells, PERMCELL HK-5P (KOKURA GLASS KOGYO) was used as the permeation experiment device. Figure 1 illustrates one of its symmetrical pair of cells. The effective area of the opening 2 to the cell 1 is 0.64 cm², and the effective capacity of the cell 1 is 5.0 ml. The water jacket of the device is connected to a circulating thermostatic bath by silicone tubing to keep the temperature of the cell interior at 37°C. The interior of the cell is constantly stirred with a magnetic stirrer (1200 rpm).

45

(3) Preparation of skin samples

50

[0036] Scratch-free abdominal skin of female hairless mice of 8 to 11-week old (Hr/Kud strain) was cut out and attached fat was removed using anatomical scissors.

(4) Drug permeation experiment using skin samples

55

[0037] Referring to Figure 1, the skin 3 of the hairless mouse obtained above is applied to cover the opening 2 (0.64 cm²) to the cell 1 (used as the receptor cell) of the side-by-side type diffusion cells. A transdermal patch 5 is applied on the skin. In order to keep it on the skin, the patch then is covered with a support net 7, which in turn is covered with

an aluminum sheet 9. The other cell is placed over the sheet, with the openings to the cells aligned, and the cells are fixed with a holder. The receptor cell is filled with 40 W/W% PEG400 aqueous solution and kept at 37°C. At predetermined intervals, 100 µL samples are removed and the amount of the drug transferred to the receptor cell through the skin is determined by HPLC under the conditions indicated in (6) below. To keep the liquid volume in the receptor cell constant, the same amount of 40 W/W% PEG400 aqueous solution is supplemented after each sampling. Under these conditions, the permeability of the skin to a drug is kept substantially constant for at least 48 hours.

(5) In vivo test-1

[0038] Male Wistar/ST rats of 8-week old (body weight approx. 250 g), which had been removed of the hair, were used to examine the transfer of drugs from the transdermal patches to the plasma (prednisolone and SJA6017) and to the ocular tissues (prednisolone). For measuring transfer of the drugs into the plasma, cervical vein cannulation had been performed in advance to allow sampling of the blood over time. The above transdermal patches, No. P5 (prednisolone) and No. S4 (SJA 6017) with the surface area of 10 cm² were applied on the abdominal skin. 0.5-ml blood sampling was performed over time through a sampling port of the cannula placed on the occipital region of the rat's head. For measurement of transfer of the drug to the ocular tissues, rats were euthanized with an excess amount of sodium pentobarbital solution and the ocular tissues were removed. The tissues were pretreated, extracted and measured to determine the concentration of the drug by HPLC.

(6) In vivo test-2

[0039] A study of SJA6017-containing transdermal patch according to the formula below was made for examining transfer of SJA6017 from the patch to the plasma and to the ocular tissues, and comparison of the results with those from intravenous injection was also made.

(Formula)	
SJA6017	0.15 g (5 W/W%)
EA09905	0.6 g (20 W/W%)
Isopropyl myristate	0.6g (20 W/W%)
Acrylic adhesive (PE-300)	1.6336 g
Coagulation enhancer (CK-401)	0.0016 5 g
Total	3.00 g

[0040] Male 9-week old Wistar/ST rats (body weight approx. 280-300 g), which had been removed of the hair, were used for the percutaneous absorption experiment. The hair was removed under anesthesia with a clipper and a shaver carefully to avoid injuring the skin. A SJA6017 transdermal patch having a drug-containing layer according to the above formula with the size of 5.0 x 6.0 cm (30 cm²) was applied to the animals (n=10) of the percutaneous administration group on the abdominal skin and secured in position with a supporting tape to prevent it from falling. After 12 hours of application, the animals were sacrificed and the blood was collected from the abdominal aorta, and the plasma separated. The eyes were excised at the same time. Each of the eyes was separated into the aqueous humor, the lens and the other tissues (consisting of the cornea, the sclera, the iris-ciliary body, the vitreous body and the retina-choroid), and corresponding tissues separated from the 20 eyes were combined, respectively, to make a sample.

[0041] An intravenous administration experiment was carried out using 5 male Wistar rats (body weight approx. 600 g: 592 ± 34 g) by administering 2 mg/kg SJA6017 through the tail vein of the animals under pentobarbital anesthesia. For the administration, a solution was used containing 10 mg SJA6017 dissolved in 10 ml mixture of ethanol/PEG400/water (1/2/1). Fifteen minutes after the intravenous administration, the animals were sacrificed, the blood was collected through the abdominal aorta, and the plasma separated. The eyes were excised at the same time. Each of the eyes was separated into the aqueous humor, the lens and the other tissues (consisting of the cornea, the sclera, the iris-ciliary body, the vitreous body and the retina-choroid), and corresponding tissues separated from the 10 eyes were combined, respectively, to make a sample.

(7) Determination of the concentration of the drugs in the samples

(a) Determination of prednisolone concentration

[0042] Determination of prednisolone (hereinafter also referred to as "PN") concentration in the samples was carried

out by HPLC under the following conditions.

Column: CAPCELL PAK CN UG120 5 μ m, 4.6 mm ϕ \times 250 mm
 Guard column: CAPCELL PAK CN UG120 5 μ m, 4.6 mm ϕ \times 35 mm
 5 Detection: UV-254 nm
 Mobile phase: acetonitrile/water = 30/70
 Flow rate: 1.0 ml/min
 Temperature: 40 $^{\circ}$ C
 Injection volume: 50 μ l or 100 μ l
 10 Retention time: approx. 6-7 minutes

(b) Determination of the concentration of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal

[0043] Determination of the concentration of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal in the samples was carried
 15 out by HPLC under the following conditions.

(i) In vitro test (concentration in the receptor cell)

[0044]

20 Column: BECKMAN ULTRASPHERE ODS 5 μ m 2.0 mm ϕ \times 250 mm
 Detection: UV-250 nm
 Mobile phase: 1 % trifluoroacetic acid in a mixture of acetonitrile/water (35/65)
 Flow rate: 0.25 ml/min
 25 Temperature: 45 $^{\circ}$ C
 Injection volume: 100 μ l
 Retention time: approx. 16 min

(ii) In vivo test

30

[0045]

Column: CAPCELL PAK C₁₈ SG120 5 μ m 4.6 mm ϕ \times 250 mm
 Detection: UV-272 nm
 35 Mobile phase: 0.02 M phosphate buffer (pH 7):acetonitrile = 45:55
 Flow rate: 1.0 ml/min
 Temperature: 40 $^{\circ}$ C
 Injection volume: 100 μ l
 Retention time: approx. 14 min

40

[Test results]

<Test results obtained using percutaneous permeation experiment device>

45 [0046] Tables 3-6 and Figures 2-5 shows accumulative amounts (in μ g/cm²) of prednisolone and N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) transferred into the receptor cell 36 or 42 hours after start of the tests using the percutaneous permeation experiment device.

[0047] As shown in Tables 3-5 and Figures 2-4, the percutaneous permeation of prednisolone from the transdermal patches P2-P10, which contained polyoxyethylene oleyl ether and/or isopropyl myristate, was greatly improved compared with the control (P1).
 50

Table 3

Time (hr)	P1 (Control)		P5		P4		P3		P2	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

55

EP 1 221 315 A1

Table 3 (continued)

Time (hr)	P1 (Control)		P5		P4		P3		P2	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
2	0.00	0.00	1.27	0.60	0.53	0.12	0.12	0.02	0.16	0.03
3	0.00	0.00	4.33	1.18	1.96	0.50	0.39	0.10	0.51	0.11
6	0.00	0.00	20.21	3.61	9.83	2.17	2.94	0.43	3.23	0.00
9	0.00	0.00	42.64	6.22	21.54	4.56	7.60	1.41	6.82	0.61
12	0.00	0.00	69.04	8.98	32.78	5.46	13.30	1.67	11.18	1.14
18	0.30	0.06	135.47	14.46	59.69	9.70	28.20	3.75	21.72	1.86
24	0.45	0.08	158.94	10.10	86.49	14.76	45.13	5.85	33.56	3.21
30	0.60	0.11	266.44	13.98	144.41	29.40	60.00	4.14	46.51	4.13
36	0.78	0.14	316.72	14.27	166.61	24.41	77.53	6.57	59.92	4.35
42	-	-	348.41	12.21	206.23	35.21	92.59	8.02	72.56	4.97

Table 4

Time (hr)	P1 (Control)		P6		P7		P8	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
2	0.00	0.00	0.00	0.00	0.00	0.00	0.19	0.08
3	0.00	0.00	0.00	0.00	0.23	0.04	0.55	0.26
6	0.00	0.00	0.57	0.19	1.64	0.50	3.64	1.70
9	0.00	0.00	1.40	0.51	4.18	1.37	8.30	3.73
12	0.00	0.00	2.43	0.79	7.29	2.44	13.51	5.88
18	0.30	0.06	5.21	1.63	14.28	4.95	25.13	10.12
24	0.45	0.08	8.77	2.77	23.15	7.86	37.82	14.79
30	0.60	0.11	11.11	2.65	32.43	10.86	50.68	17.84
36	0.78	0.14	14.87	3.23	42.83	14.86	64.74	21.97
42	-	-	19.92	4.01	53.42	18.84	79.33	24.83

Table 5

Time (hr)	P1 (Control)		P9		P10	
	Mean	SD	Mean	SD	Mean	SD
0	0.00	0.00	0.00	0.00	0.00	0.00
1	0.00	0.00	0.00	0.00	0.00	0.00
2	0.00	0.00	0.00	0.00	0.00	0.00
3	0.00	0.00	0.00	0.00	0.00	0.00
6	0.00	0.00	0.00	0.00	0.57	0.10
9	0.00	0.00	0.73	0.12	1.29	0.17
12	0.00	0.00	1.19	0.19	1.93	0.21

Table 5 (continued)

Time (hr)	P1 (Control)		P9		P10	
	Mean	SD	Mean	SD	Mean	SD
18	0.30	0.06	1.96	0.28	3.26	0.29
24	0.45	0.08	2.51	0.32	4.64	0.39
30	0.60	0.11	3.18	0.40	5.60	1.05
36	0.78	0.14	4.14	0.55	7.66	0.52

[0048] As to N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal, it is shown in Table 5 and Figure 5 that percutaneous permeation was clearly noted with transdermal patches S2-S4 of the present invention while no percutaneous permeation was observed with the control (S1).

Table 6

Time (hr)	S1 (Control)		S2		S3		S4	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
6	0.00	0.00	3.19	0.33	6.15	3.47	4.97	1.47
12	0.00	0.00	9.63	2.04	13.80	7.75	16.65	6.59
18	0.00	0.00	17.16	1.97	26.35	11.87	27.32	11.75
24	0.00	0.00	26.07	2.69	41.14	16.45	39.67	16.12
30	0.00	0.00	33.67	4.81	57.59	20.63	49.68	21.14
36	0.00	0.00	42.83	5.80	78.83	26.75	62.37	25.57
48	0.00	0.00	62.48	8.58	111.32	38.71	88.36	37.86

<The results of in vivo test>

(1) Plasma concentration of the drugs after application of transdermal patches (in vivo test-1)

[0049] Table 7 below and Figure 6 show the profiles of plasma concentration of prednisolone and N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6107) after application of the aforementioned transdermal patches (10 cm²) indicated above as Nos. P5 and S5, respectively, which contained one of those drugs, to the skin of the animals. After the application, the plasma concentration of the drugs gradually rose and reached the peaks at 8 and 12 hours after application for prednisolone and SJA6017, respectively. Though the concentration of the drugs gradually lowered afterwards, substantial concentration of the drugs was noted even 24 hours after the application, when SJA6017 concentration, in particular, was still maintained at about 85 % of its peak.

Table 7

Time (hr)	SJA6017			Prednisolone		
	Plasma concentration	SD	n	Plasma concentration	SD	n
0	0	0	5	0	0	5
2	30	5	6	220	233	16
4	36	7	2	288	190	5
6	58	28	6	385	245	15
8	50	19	2	608	344	7
12	114	56	9	148	43	7
18	68	24	4	99	25	4

Table 7 (continued)

Time (hr)	SJA6017			Prednisolone		
	Plasma concentration	SD	n	Plasma concentration	SD	n
24	98	8	5	77	30	5
Unit: ng/ml						

(2) Intraocular concentration of prednisolone (in vivo test-1)

[0050] Prednisolone amount was determined in the plasma and the eyeball of the rats to which were applied a 3 % prednisolone-containing preparation, P5. As a result, 70 ng/g prednisolone was detected 6 hours after the application of the preparation. This indicates that prednisolone was transferred to the interior of the eye at a concentration that was equivalent to 18 % of the plasma concentration (Table 8). As all the samples were collected at a time, 6 hours after the application, because it was necessary to combine multiple eyes for extraction due to the minute amount of ocular tissues, no measurement could be made at any other point.

(3) Plasma and intraocular concentration of SJA6017 (in vivo test-2)

[0051] Table 8 shows the concentration of SJA6017 in the eyeball and in the plasma after the application of the SJA6017-containing transdermal patches, in comparison with corresponding values after intravenous administration of SJA6017. Also included in the table are the results of prednisolone transdermal administration in the above in vivo test-1.

Table 8

	SJA6017 transdermal application	SJA6017 intravenous injection	Prednisolone transdermal application
Point of measument	12 hours after application	15 minutes after intravenous injection	6 hours after application
Plasma concentration [ng/ml]	47±12	120±16	385
Intraocular concentration [ng/g eye]	7.2	16	70
Eyeball/plasma ratio	16 %	13 %	18 %
[Intraocular concentration, itemized]			
Aqueous humor [ng/ml]	not detected	not detected	-
Lens [ng/g tissue]	1.1 (2.3%)*2	not detected	-
Other ocular tissues*1 [ng/g tissues]	13.8 (29.6%)*2	33.4 (27.8%)*2	-

*1 Other ocular tissues: cornea, sclera, iris-ciliary body, vitreous body, retina-choroid

*2 Ratio to plasma concentration (100 %)

[0052] Table 8 shows that 7.2 ng/g of SJA6017 was detected in the eyeball 12 hours after the application of the SJA6017-containing preparation. This value reaches about 16 % of the plasma concentration of the drug, and is higher than the corresponding value (13 %) detected after intravenous application. This indicates continuous nature of absorption of SJA6017 from the patch and that this method of administration of a drug by transdermal patches is a method available to continuously transfer a drug from the plasma into the eyeball.

[0053] The drug was detected in other parts of the eyeball than the aqueous humor. Among the parts other than the aqueous humor, drug transfer was higher in the tissues including the iris-ciliary body, the vitreous body, the retina-choroid. These results indicate that a transdermal patch is a suitable form for long-term application of a drug to intraocular tissues.

[Examples]

[0054] The present invention is described in further detail with reference to examples. It is not intended, however, that the present invention be limited to the examples.

<Example 1> Acrylic patches

[0055] Acrylic patches containing 5 W/W% (0.15 g) of a drug (prednisolone or SJA6017) and 30 W/W% (0.9 g) of polyoxyethylene oleyl ether (NOFABLE EAO-9905: NOF CORPORATION) as a percutaneous absorption enhancer in the drug-containing layer were prepared according to the following formula. Briefly, prednisolone and about 1.0 ml of toluene was mixed and sonicated for about 30 seconds in a disposable cup to dissolve or disperse the drug. Polyoxyethylene oleyl ether was added to this and mixed well. Then, 5.0 g of the acrylic adhesive (PE-300: NIPPON CARBIDE INDUSTRIES CO., INC.), which served as a dispersion base, and 0.2 g of the coagulation agent (CK-401: NIPPON CARBIDE INDUSTRIES CO., INC.) were added in this order and mixed well. The mixture was degassed, spread over a release membrane with a doctor knife or a baker applicator (JAPAN APPLIED TECHNOLOGY), and left stand until the organic solvent evaporated. A lining film was placed over this, glued to it with pressure using a roller, and put in a thermostatic chamber at about 40 °C for 8-12 hours to cross-linking to take place.

(Formula)	
Drug	0.15 g
Polyoxyethylene oleyl ether	0.9 g
Acrylic adhesive (PE-300)	5.0 g
Coagulation enhancer (CK-401)	0.2 g
Toluene	1.0 ml

<Example 2> Acrylic patches

[0056] Acrylic patches containing 10 W/W% (0.3 g) of a drug (prednisolone or SJA6017) and 20 W/W% (0.6 g) of polyoxyethylene oleyl ether (NOFABLE EAO-9905: NOF CORPORATION) as a percutaneous absorption enhancer in the drug-containing layer were prepared in the same manner as in Example 1 according to the following formula.

(Formula)	
Drug	0.3 g
Polyoxyethylene oleyl ether	0.6 g
Acrylic adhesive (PE-300)	5.0 g
Coagulation enhancer (CK-401)	0.2 g
Toluene	1.0 ml

<Example 3> Acrylic patches

[0057] Acrylic patches containing 15 W/W% (0.45 g) of a drug (prednisolone or SJA6017) and 20 W/W% (0.6 g) of polyoxyethylene oleyl ether (NOFABLE EAO-9905: NOF CORPORATION) as a percutaneous absorption enhancer in the drug-containing layer were prepared in the same manner as in Example 1 according to the following formula.

(Formula)	
Drug	0.45 g
Polyoxyethylene oleyl ether	0.6 g
Acrylic adhesive (PE-300)	5.0 g
Coagulation enhancer (CK-401)	0.2 g
Toluene	1.0 ml

<Example 4> Acrylic patches

[0058] Acrylic patches containing 5 W/W% (0.15 g) of a drug (prednisolone or SJA6017), 10 W/W% (0.3 g) of poly-

EP 1 221 315 A1

oxyethylene oleyl ether (NOFABLE EAO-9905: NOF CORPORATION), and 20 W/W% (0.6 g) isopropyl myristate in the drug-containing layer were prepared in the same manner as in Example 1 according to the following formula.

(Formula)	
Drug	0.15 g
Polyoxyethylene oleyl ether	0.3 g
Isopropyl myristate	0.6 g
Acrylic adhesive (PE-300)	5.0 g
Coagulation enhancer (CK-401)	0.2 g
Toluene	1.0 ml

<Example 5> Acrylic patches

[0059] Acrylic patches containing 10 W/W% (0.3 g) of a drug (prednisolone or SJA6017), 20 W/W% (0.6 g) of polyoxyethylene oleyl ether (NOFABLE EAO-9905: NOF CORPORATION), and 10 W/W% (0.3 g) isopropyl myristate in the drug-containing layer were prepared in the same manner as in Example 1 according to the following formula.

(Formula)	
Drug	0.3 g
Polyoxyethylene oleyl ether	0.6 g
Isopropyl myristate	0.3 g
Acrylic adhesive (PE-300)	5.0 g
Coagulation enhancer (CK-401)	0.2 g
Toluene	1.0 ml

<Example 6> Silicone-based patches

[0060] Silicone-based patches containing 5 W/W% (0.33 g) of a drug (prednisolone or SJA6017) and 20 W/W% (1.34 g) of polyoxyethylene oleyl ether (NOFABLE EAO-9905: NOF CORPORATION) as a percutaneous absorption enhancer in the drug-containing layer were prepared according to the following formula. Briefly, prednisolone and polyoxyethylene oleyl ether were mixed well in a disposable cup and, after addition of about 2.5 ml of ethyl acetate, sonicated for about 30 seconds to dissolve or disperse the drug. To this were added 0.25 g of silicone oil (360 medical fluid, 20 cs: DOW CORNING ASIA), 4.5 g of a silicone elastomer (SLASTIC MDX4-4210, medical grade: DOW CORNING ASIA), and 0.25 g of a curing agent (curing agent for SLASTIC MDX4-4210: DOW CORNING ASIA) in the order and mixed well. The mixture was degassed, spread over a backing liner (Cerafeel #25) with a doctor knife or a baker applicator (JAPAN APPLIED TECHNOLOGY), left stand for 1 hour at room temperature, allowed to cure at 40 °C, and cut into a predetermined size to give silicone-based transdermal patches.

(Formula)	
Drug	0.33 g
Polyoxyethylene oleyl ether	1.34 g
Silicone elastomer	4.5 g
Silicone oil	0.25 g
Curing agent	0.25 g
Ethyl acetate	2.5 ml

<Example 7> Silicone-based patches

[0061] Silicone-based patches containing 10 W/W% (0.83 g) of a drug (prednisolone or SJA6017) and 30 W/W% (2.5 g) of polyoxyethylene oleyl ether (NOFABLE EAO-9905: NOF CORPORATION) as a percutaneous absorption enhancer in the drug-containing layer were prepared in the same manner as in Example 6 according to the following formula

(Formula)	
Drug	0.83 g
Polyoxyethylene oleyl ether	2.5 g
Silicone elastomer	4.5 g
Silicone oil	0.25 g
Curing agent	0.25 g
Ethyl acetate	2.5 ml

<Example 8> Silicone-based patches

[0062] Silicone-based patches containing 10 W/W% (0.83 g) of a drug (prednisolone or SJA6017), 10 W/W% (0.83 g) of polyoxyethylene oleyl ether (NOFABLE EAO-9905: NOF CORPORATION) and 20 W/W% (1.67 g) of isopropyl myristate in the drug-containing layer were prepared in the same manner as in Example 6 according to the following formula.

(Formula)	
Drug	0.83 g
Polyoxyethylene oleyl ether	0.83 g
Isopropyl myristate	1.67 g
Silicone elastomer	4.5 g
Silicone oil	0.25 g
Curing agent	0.25 g
Ethyl acetate	2.5 ml

<Example 9> Silicone-based patches

[0063] Silicone-based patches containing 15 W/W% (1.15 g) of a drug (prednisolone or SJA6017), 10 W/W% (0.77 g) of polyoxyethylene oleyl ether (NOFABLE EAO-9905: NOF CORPORATION) and 10 W/W% (0.77 g) of isopropyl myristate in the drug-containing layer were prepared in the same manner as in Example 6 according to the following formula.

(Formula)	
Drug	1.15 g
Polyoxyethylene oleyl ether	0.77 g
Isopropyl myristate	0.77 g
Silicone elastomer	4.5 g
Silicone oil	0.25 g
Curing agent	0.25 g
Ethyl acetate	2.5 ml

<Example 10> Styrene-isoprene-styrene copolymer-based patches

[0064] Styrene-isoprene-styrene copolymer-based patches containing 5 W/W% (0.15 g) of a drug (prednisolone or SJA6017) and 30 W/W% (0.9 g) of polyoxyethylene oleyl ether (NOFABLE EAO-9905: NOF CORPORATION) as a percutaneous absorption enhancer in the drug-containing layer were prepared according to the following formula. Briefly, 0.9 g of styrene-isoprene-styrene copolymer (CARIFLEX TR-1107: SHELL CHEMICAL) was dissolved in 1.05 g of liquid paraffin at about 100 °C. To this were added the drug and polyoxyethylene oleyl ether and mixed well. The mixture was spread over a backing liner (Cerafeel # 25) with a doctor knife or a bake applicator (JAPAN APPLIED TECHNOLOGY), and cut into a predetermined size to give styrene-isoprene-styrene copolymer-based transdermal patches.

(Formula)	
Drug	0.15 g
Polyoxyethylene oleyl ether	0.9 g
Styrene-isoprene-styrene copolymer	0.9 g
Liquid paraffin	0.15 g

<Example 11> Styrene-isoprene-styrene copolymer-based patches

[0065] Styrene-isoprene-styrene copolymer-based patches containing 5 W/W% (0.15 g) of a drug (prednisolone or SJA6017), 20 W/W% (0.6 g) of polyoxyethylene oleyl ether (NOFABLE EAO-9905: NOF CORPORATION) and 10 W/W% (0.3 g) of isopropyl myristate in the drug-containing layer were prepared in the same manner as in Example 10 according to the following formula.

(Formula)	
Drug	0.15 g
Polyoxyethylene oleyl ether	0.6 g
Isopropyl myristate	0.3 g
Styrene-isoprene-styrene copolymer	0.9 g
Liquid paraffin	0.15 g


INDUSTRIAL APPLICABILITY

[0066] The present invention provides pharmaceutical preparations for administration of drugs for treating diseases of the posterior segment of the eye, which preparation will make it easier to achieve improved patients' compliance, and minimize burden on the patients, and eliminate unnecessary patients' risks.

Claims


1. An ophthalmic transdermal patch for treating diseases of the posterior segment of the eye comprising a drug-containing layer uniformly containing in a base matrix a percutaneous absorption enhancer and a drug to be delivered to at least a part of the posterior segment of the eye including the lens, the vitreous body, the choroid and the retina.
2. The ophthalmic transdermal patch of claim 1 wherein the drug is an anti-cataract agent, an anti-inflammatory agent, an anti-viral agent, an immunosuppressant, a calcium channel antagonist, a glutamate receptor antagonist or a cysteine protease inhibitor.
3. The transdermal patch of claim 1 or 2 wherein the percutaneous absorption enhancer is polyoxyethylene oleyl ether and/or isopropyl myristate.
4. The ophthalmic transdermal patch of one of claims 1 to 3 wherein the content of polyoxyethylene oleyl ether in the drug-containing layer is 5-30 W/W%.
5. The ophthalmic transdermal patch of one of claims 1 to 4 wherein the content of isopropyl myristate in the drug-containing layer is 5-30 W/W%.
6. The ophthalmic transdermal patch of one of claims 1 to 5 wherein the base matrix comprises acrylic adhesive, silicone elastomer or styrene-isoprene-styrene copolymer.
7. The ophthalmic transdermal patch of one of claims 1 to 6 wherein the ratio of the content by weight concentration (W/W%) of polyoxyethylene oleyl ether to isopropyl myristate is in the range of 1:0.1-1:5 in the drug-containing layer.
8. The ophthalmic transdermal patch of one of claims 1 to 7 wherein the drug is a steroidal drug.

9. The ophthalmic transdermal patch of one of claims 1 to 7 wherein the drug is a compound of the formula (1)



15 or a pharmaceutically acceptable salt thereof, wherein R¹ denotes C1-C4 alkyl, or C6-C10 aryl which may be substituted, R² and R³ are the same or different from each other and denote hydrogen or C1-C4 alkyl, or are combined to form a C3-C7 ring, and R⁴ denotes aryl, cycloalkyl, or a lower alkyl which may be substituted with an aromatic heterocyclic ring.


- 20 10. The ophthalmic transdermal patch of claim 9 wherein the drug is N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal or a pharmaceutically acceptable salt thereof.
- 25 11. A method for treating a disease of at least a part of the posterior segment of the eye including the lens, the vitreous body, the choroid and the retina in an animal including a human, wherein the method comprises applying to the animal a transdermal patch comprising a drug-containing layer uniformly containing in a base matrix an effective amount of a drug to be delivered to the part and a percutaneous absorption enhancer.
- 30 12. The method of claim 11 wherein the drug is an anti-cataract agent, an anti-inflammatory agent, an anti-viral agent, an immunosuppressant, a calcium channel antagonist, a glutamate receptor antagonist or a cysteine protease inhibitor.
- 35 13. The method of claim 11 wherein the percutaneous absorption enhancer is polyoxyethylene oleyl ether and/or isopropyl myristate.
- 40 14. The method of claim 13 wherein the content of polyoxyethylene oleyl ether in the drug-containing layer is 5-30 W/W%.
- 45 15. The method of claim 13 wherein the content of isopropyl myristate in the drug-containing layer is 5-30 W/W%.
16. The method of claim 11 wherein the base matrix comprises acrylic adhesive, silicone elastomer or styrene-isoprene-styrene copolymer.
17. The method of claim 13 wherein the ratio of the content by weight concentration (W/W%) of polyoxyethylene oleyl ether to isopropyl myristate is in the range of 1:0.1-1:5 in the drug-containing layer.
18. The method of claim 11 wherein the drug is a steroidal drug.
- 50 19. The method of claim 11 wherein the drug is a compound of the formula (1)





(1)


or a pharmaceutically acceptable salt thereof, wherein R¹ denotes C1-C4 alkyl, or C6-C10 aryl which may be substituted, R² and R³ are the same or different from each other and denote hydrogen or C1-C4 alkyl, or are combined to form a C3-C7 ring, and R⁴ denotes aryl, cycloalkyl, or a lower alkyl which may be substituted with an aromatic heterocyclic ring.


20. The method of claim 19 wherein the drug is N-(4-fluorophenyl-sulfonyl)-L-valyl-L-leucinal or a pharmaceutically acceptable salt thereof.

















INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/06815

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl.⁷ A61K31/198, A61K31/573, A61K9/70,
A61K45/00, A61K47/34, A61K47/14, A61P27/12,
A61P29/00, A61P31/12, A61P37/06, A61P43/00 111

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl.⁷ A61K31/198, A61K31/573, A61K9/70,
A61K45/00, A61K47/34, A61K47/14, A61P27/12,
A61P29/00, A61P31/12, A61P37/06, A61P43/00 111

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP, 63-218631, A (Sekisui Chemical Co., Ltd.), 12 September, 1988 (12.09.88), Full text (Family: none)	1,2,6,8 3-5,7, 9,10
X	US, 5700480, A (LTS LOHMANN THERAPIE-SYSTEME GMBH & CO), 23 December, 1997 (23.12.97), especially, Claims & JP, 8-505632, A, especially, Claims & DE, 4301783, A & WO, 9416707, A1 & AU, 9458817, A & ZA, 9400414, A & NO, 9502907, A & FI, 9503533, A & EP, 680325, A1 & CZ, 9501842, A & NZ, 259857, A & SK, 9500889, A & IL, 108235, A	1-3,5,6 4,7-10
X	JP, 5-255118, A (Hisamitsu Pharmaceutical Co., Inc.), 05 October, 1993 (05.10.93), Full text (Family: none)	1,2,8 9,10 3-7
Y	EP, 771565, A2 (SENJYU PHARM CO LTD), 07 May, 1997 (07.05.97), Full text	9,10 1-8

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not
considered to be of particular relevance
"E" earlier document but published on or after the international filing
date
"L" document which may throw doubts on priority claim(s) or which is
cited to establish the publication date of another citation or other
special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other
means
"P" document published prior to the international filing date but later
than the priority date claimed

"I" later document published after the international filing date or
priority date and not in conflict with the application but cited to
understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be
considered novel or cannot be considered to involve an inventive
step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be
considered to involve an inventive step when the document is
combined with one or more other such documents, such
combination being obvious to a person skilled in the art
"A" document member of the same patent family

Date of the actual completion of the international search
06 November, 2000 (06.11.00)

Date of mailing of the international search report
21 November, 2000 (21.11.00)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/06815

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	& JP, 10-147564, A Full text & AU, 9670384, A & NO, 9604514, A & CA, 2188817, A & ZA, 9608947, A & HU, 9602943, A & BR, 9605267, A & MX, 9605156, A & US, 6057290, A & AU, 200036404, A & KR, 97020115, A	
A	JP, 7-145061, A (Sekisui Chemical Co., Ltd.), 06 June, 1995 (06.06.95), Full text (Family: none)	1-10
PA	WO, 9953906, A1 (HISAMITSU PHARM CO LTD), 28 October, 1999 (28.10.99), Full text & JP, 11-302161, A, Full text & AU, 9931666, A	1-10

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/06815

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 11-22
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 11 to 22 pertain to diagnostic methods to be practiced on the human body and thus relate to a subject matter which this International Searching Authority is not required to search.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.